PMID: 6107543Oct 25, 1980Paper

Long-term follow-up of children with familial hypercholesterolaemia treated with cholestyramine

Lancet
R J WestJ V Leonard

Abstract

35 children with the heterozygous form of familial hypercholesterolaemia (FH) who were followed for up to 8 years after starting on cholestyramine treatment showed a progressive decrease in compliance with therapy with time, so that only 55% remained on treatment after 6 years and only 48% after 8 years. Long-term compliance was significantly better in those starting treatment before age 10. Plasma-cholesterol was lowered in all children taking cholestyramine: for the group the mean reduction in plasma-cholesterol ranged from 26 to 44% during the years of the study, on a mean cholestyramine dose of around 0.4 g/kg/day. Cholestyramine thus effectively lowers plasma-cholesterol in FH, but for long-term use compliance is a problem in many children.

References

Feb 1, 1975·Gut·R J West, J K Lloyd
May 1, 1973·Archives of Disease in Childhood·R J West, J K Lloyd
Jun 17, 1972·British Medical Journal·J M DarmadyJ K Lloyd

❮ Previous
Next ❯

Citations

Feb 1, 1990·Journal of Clinical Pharmacology·M Ast, W H Frishman
Nov 10, 2009·Journal of Inherited Metabolic Disease·A van der GraafA Wiegman
Dec 21, 2000·Current Atherosclerosis Reports·D M Black
Jan 5, 2014·Paediatric Drugs·Marjet J A M BraamskampJohn J P Kastelein
Jan 1, 1990·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·A M KesslingS E Humphries
Sep 6, 2003·Lancet·Paul Durrington
Aug 1, 1987·Baillière's Clinical Endocrinology and Metabolism·D Bilheimer
Feb 27, 2001·Progress in Pediatric Cardiology·T J. Starc
Jan 1, 1991·Acta Paediatrica Scandinavica. Supplement·J K Lloyd
Sep 1, 1992·Acta Paediatrica·B KoletzkoU Wendel
Sep 1, 1996·Acta Paediatrica·S Tonstad, L Ose
Jan 1, 1991·Annals of the New York Academy of Sciences·J M Hoeg
Jan 1, 1985·Archives of Disease in Childhood·K A WheelerJ Barley
Feb 1, 1996·Archives of Disease in Childhood·S TonstadL Ose
Feb 1, 1986·Postgraduate Medical Journal·J K Lloyd, R J West
Mar 19, 2004·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·B KasiskeUNKNOWN National Kidney Foundation
Jan 24, 2017·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Chiara MameliCristiana Perrotta
May 21, 2004·Expert Review of Cardiovascular Therapy·Alpo F VuorioHelena Gylling
Aug 16, 2015·Current Cardiology Reports·Ilse K LuirinkAlbert Wiegman
Sep 18, 2015·Arteriosclerosis, Thrombosis, and Vascular Biology·Robert A HegeleFrancine K Welty
Sep 1, 2008·Expert Review of Endocrinology & Metabolism·Lorenzo IughettiFiorella Balli
Aug 2, 2017·Expert Review of Clinical Pharmacology·Albert Wiegman, Barbara A Hutten
Jun 17, 1991·The Medical Journal of Australia·T J BoultonA M Magarey
Sep 1, 1992·Current Problems in Cardiology·J S Prihoda, D R Illingworth
Feb 1, 1993·The Journal of Pediatrics·M BeckerK Von Bergmann

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.